ZNTL

MKT CAP:$286M

Zentalis Pharmaceuticals, Inc.

Market Cap

$286M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.89+$2.52 (+183.94%)

Apr 23, 2026

Company Details

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor ...

CEO

Julie Eastland

IPO Date

Apr 3, 2020

Website

zentalis.com

Key Metrics TTM

Revenue

$0

-100.0% YoY

Net Income

-$137M

EPS (Diluted)

-$1.90

Free Cash Flow

-$125M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 26, 2026

$0-100.0%EPS -$1.91

Q4 2025

Mar 26, 2026

$0-100.0%EPS -$0.49

Q3 2025

Nov 10, 2025

$0EPS -$0.37

Q2 2025

Aug 6, 2025

$0EPS -$0.37

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$58M
Q2 22	$0	$0	-$63M
Q3 22	$0	$0	-$54M
Q4 22	$0	$0	-$52M
Q1 23	$0	$0	-$65M
Q2 23	$0	$0	-$104M
Q3 23	$0	$0	-$63M
Q4 23	$0	$0	-$68M
Q1 24	$41M	$40M	-$25M
Q2 24	$0	$0	-$65M
Q3 24	$0	$0	-$51M
Q4 24	$27M	$27M	-$50M
Q1 25	$0	$0	-$46M
Q2 25	$0	$0	-$36M
Q3 25	$0	$0	-$34M
Q4 25	$0	-$157.0K	-$37M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	28.2x	—
Q2 24	7.3x	—
Q3 24	6.4x	—
Q4 24	3.1x	—
Q1 25	4.2x	—
Q2 25	3.1x	—
Q3 25	4.0x	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$50M	-$51M
Q2 22	-$43M	-$43M
Q3 22	-$33M	-$35M
Q4 22	-$37M	-$37M
Q1 23	-$49M	-$49M
Q2 23	-$79M	-$80M
Q3 23	-$39M	-$39M
Q4 23	-$41M	-$41M
Q1 24	-$52M	-$52M
Q2 24	-$35M	-$35M
Q3 24	-$44M	-$44M
Q4 24	-$40M	-$40M
Q1 25	-$33M	-$33M
Q2 25	-$35M	-$35M
Q3 25	-$27M	-$27M
Q4 25	-$31M	-$31M

Capital Expenditures

Quarter	CapEx
Q1 22	$450.0K
Q2 22	$278.0K
Q3 22	$2M
Q4 22	$160.0K
Q1 23	$0
Q2 23	$319.0K
Q3 23	$91.0K
Q4 23	$173.0K
Q1 24	$40.0K
Q2 24	$181.0K
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+66.5%
Q2 22	—	+57.7%
Q3 22	—	+7.6%
Q4 22	—	+7.4%
Q1 23	—	+12.2%
Q2 23	—	+63.7%
Q3 23	—	+15.7%
Q4 23	—	+31.2%
Q1 24	—	+0.6%
Q2 24	—	-37.3%
Q3 24	—	-18.0%
Q4 24	—	+12.9%
Q1 25	-100.0%	-30.2%
Q2 25	—	-44.7%
Q3 25	—	-34.4%
Q4 25	-100.0%	-51.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$10M	—
Q2 22	$17M	—
Q3 22	$10M	—
Q4 22	$10M	—
Q1 23	$14M	—
Q2 23	$13M	—
Q3 23	$14M	—
Q4 23	$0	—
Q1 24	$13M	31.6%
Q2 24	$13M	—
Q3 24	$10M	—
Q4 24	$31M	116.7%
Q1 25	$6M	—
Q2 25	$6M	—
Q3 25	$5M	—
Q4 25	$3M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$46M	$12M	—
Q2 22	$44M	$20M	—
Q3 22	$42M	$12M	—
Q4 22	$41M	$11M	—
Q1 23	$49M	$16M	—
Q2 23	$43M	$16M	—
Q3 23	$47M	$16M	—
Q4 23	$52M	$16M	—
Q1 24	$50M	$16M	—
Q2 24	$48M	$17M	—
Q3 24	$37M	$15M	—
Q4 24	$33M	$40M	—
Q1 25	$27M	$11M	—
Q2 25	$28M	$7M	—
Q3 25	$23M	$11M	—
Q4 25	$29M	—	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$31M	$259M	$289M
Q2 22	$55M	$400M	$455M
Q3 22	$43M	$379M	$422M
Q4 22	$43M	$394M	$437M
Q1 23	$36M	$356M	$393M
Q2 23	$267M	$286M	$553M
Q3 23	$111M	$406M	$517M
Q4 23	$28M	$455M	$483M
Q1 24	$38M	$451M	$489M
Q2 24	$37M	$389M	$426M
Q3 24	$41M	$350M	$391M
Q4 24	$34M	$337M	$371M
Q1 25	$42M	$291M	$332M
Q2 25	$38M	$266M	$303M
Q3 25	$39M	$242M	$281M
Q4 25	$36M	$210M	$246M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	45M	+0.6%	+19.2%
Q2 22	51M	+13.0%	+28.0%
Q3 22	57M	+11.1%	+40.8%
Q4 22	59M	+4.4%	+31.8%
Q1 23	59M	-0.0%	+31.0%
Q2 23	61M	+2.6%	+18.9%
Q3 23	71M	+16.2%	+24.3%
Q4 23	71M	+0.2%	+19.4%
Q1 24	71M	+0.6%	+20.1%
Q2 24	71M	-0.2%	+16.9%
Q3 24	71M	+0.1%	+0.7%
Q4 24	71M	+0.2%	+0.7%
Q1 25	72M	+0.6%	+0.7%
Q2 25	72M	+0.4%	+1.3%
Q3 25	72M	+0.2%	+1.4%
Q4 25	72M	-0.6%	+0.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	177
Q2 22	$0	177
Q3 22	$0	177
Q4 22	$0	156
Q1 23	$0	156
Q2 23	$0	156
Q3 23	$0	156
Q4 23	$0	168
Q1 24	$241.4K	168
Q2 24	$0	168
Q3 24	$0	168
Q4 24	$161.8K	166
Q1 25	$0	166
Q2 25	$0	166
Q3 25	$0	166
Q4 25	$0	200K

Revenue / Employee